title: [Combined chemotherapy of weekly paclitaxel and ifosfamide in the treatment of 23 patients with advanced non-small cell lung cancer].
abstract: BACKGROUND
  To evaluate the efficacy and safety of weekly paclitaxel and ifosfamide in the treatment of advanced non-small cell lung cancer.
  
  
  METHODS
  Twenty-three patients with advanced non-small cell lung cancer received paclitaxel 50-65 mg/m² IV weekly on days 1, 8, 15, and IFO 1.3 g/m² IV on days 2-4. The schedule was repeated every 28 days for two or three cycles as a course.
  
  
  RESULTS
  One patient had complete response and eight had partial response. Eleven patients had stable disease and three had progressive disease. The overall response rate was 39.1%. Twenty patients were followed-up. The 1-year survival was 40%(8/20) and the median survival duration was 8.9 months. The main toxicities were hematological toxicity (leukopenia, 69.6%, 16/23) and nausea/vomiting (47.8%, 11/23).
  
  
  CONCLUSIONS
  Combined chemotherapy of weekly paclitaxel and ifosfamide is a good regimen for advanced non-small cell lung cancer with good efficacy and well-tolerated side effects.
authors.affiliation: Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210009, P.R.China.
authors.forename: Hongxia
authors.initials: H
authors.lastname: Xu
authors.forename: Chunlan
authors.initials: C
authors.lastname: Nie
authors.forename: Zhuan
authors.initials: Z
authors.lastname: Hong